Gelonghui, November 22nd - Zhejiang Garden Biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceuticals Co., Ltd. (hereinafter referred to as "Garden Pharmaceuticals"), recently received the "Drug Registration Certificate" for "Alendronate Sodium Tablets" issued by the National Medical Products Administration.
Alendronate Sodium Tablets are mainly used to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. Alendronate Sodium Tablets are a Category B variety in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2023)".
